Clinical Trial Update: A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating palbociclib added to standard endocrine therapy in HR-positive, HER2-normal breast cancer with residual disease after neoadjuvant thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Breast Cancer, Hormonreceptor Positive | Phase 3 | Status: COMPLETED | Results posted: 2023-12-12